ASSESSMENT OF NEO-ADJUVANT THERAPY IN CORRELATION WITH THE PREDICTIVE ROLE OF KI67 INDEX IN CASES OF LOCALLY ADVANCED BREAST CANCER | ||
| Ain Shams Medical Journal | ||
| Article 10, Volume 73, Issue 2, June 2022, Pages 353-363 PDF (330.11 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/asmj.2022.252412 | ||
| Authors | ||
| Manar Shaaban Saleh1; Reda Abd Eltawab Khalil2; Ashraf Abd El Moghny Mostafa2; Hany Abd Elaziz3; Lobna Shash4; Yasser Mohammed Abd El Samea2 | ||
| 1General Surgery Department Ismailia, Hospital, Faculty of Medicine, Ain Shams University , Cairo, Egypt. | ||
| 2General Surgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||
| 3Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||
| 4Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||
| Abstract | ||
| Background: Neoadjuvant therapy refers to the administration of systemic therapy, either chemotherapy or endocrine therapy, prior to definitive breast surgery. Patients who derive clinical benefit from neoadjuvant chemotherapy (NACT) include patients with high-risk breast tumors, large breast tumors, and locally advanced tumors, including those initially ineligible for surgery. The goals of NACT include rendering inoperable tumors resectable, surgical down staging for patients who prefer breast conservation, and de-escalating axillary surgery in those with clinically positive nodes. Aim of the Study: To evaluate the response rate to neoadjuvant chemotherapy or hormonal therapy in cases of early breast cancer (T1, T2-N0, N1-M0) according to the TNM staging and to find the predictive value of the reduction of the prognostic value Ki-67 for the response to the neo-adjuvant treatment. Patients and Methods: This prospective study was conducted at tertiary care hospital at the breast surgery unit and clinical oncology departments, Ain Shams University Hospitals from 2015 till 2017 and performed on a total of 60 female patients with newly diagnosed early breast cancer patients according to TNM staging system. Results: During the follow-up of the patients, the current study results revealed that Ki-67was significantly decreased with significantly decreased tumor size at follow up among the studied cases. Baseline and follow up Ki-67 were lowest in complete response, followed by partial response, then stable disease and highest in progressive response, the differences statistically were significant. As a result, Ki-67 statistically had significant moderate diagnostic performance in predicting clinical responses, was highest in predicting progressive response. Conclusion: Ki-67 is a valuable marker, as it has prognostic and predictive abilities after neoadjuvant chemotherapy. Ki-67 expression may be considered a valuable potential biomarker and add a prognostic information to that obtained from classical prognostic factors such as tumor size. | ||
| Keywords | ||
| Breast Cancer; Ki67; Neo-adjuvant Therapy | ||
|
Statistics Article View: 174 PDF Download: 188 |
||
